Published on 8 Apr 2024 on Zacks via Yahoo Finance

Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study

Ocugen, Inc. OCGN announced that the Data and Safety Monitoring Board (“DSMB”) for the early to mid-stage study of its investigational candidate, OCU410, has approved the initiation of dosing with the medium dose of OCU410 in the dose-escalation phase of the study to treatpatients with geographic atrophy (GA). Per management, this marks a critical step forward in determiningthe optimal dosing regimen of OCU410.

The company’s shares jumped 21.2% in the last trading session on Apr 5 and continued to gain another 2.7% in the after-market hours following the announcement.

Ocugen previously reported positive outcomes from Cohort 1 of the phase I/II ArMaDa study, in which three GA patients, to date, were dosed with the low dose (2.5×1010 vg/mL) of OCU410. Per the data readout, no adverse events related to treatment with OCU410 have been reported to date, deeming the low dose of the candidate as safe and tolerable.